We found that SLUG was solely expressed in GBM, but not in grade II and grade III gliomas, by both tumor vascular cells and by tumoral cells, which confirms previous studies that highlighted its putative role in driving gliomagenesis and therapeutic resistance in GBM [24,25]. Here, SNAI2 is linked to central nervous system cancer.